1. Home
  2. BFS vs HROW Comparison

BFS vs HROW Comparison

Compare BFS & HROW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Saul Centers Inc.

BFS

Saul Centers Inc.

N/A

Current Price

$28.57

Market Cap

902.2M

Sector

Real Estate

ML Signal

N/A

HROW

Harrow Inc.

N/A

Current Price

$26.73

Market Cap

1.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BFS
HROW
Founded
1993
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
902.2M
1.1B
IPO Year
1996
2008

Fundamental Metrics

Financial Performance
Metric
BFS
HROW
Price
$28.57
$26.73
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
9
Target Price
$43.00
★ $63.00
AVG Volume (30 Days)
121.8K
★ 582.5K
Earning Date
11-05-2026
11-09-2026
Dividend Yield
★ 8.19%
N/A
EPS Growth
N/A
★ 71.43
EPS
★ 0.78
N/A
Revenue
★ $289,843,000.00
N/A
Revenue This Year
$7.44
$28.41
Revenue Next Year
$3.40
$58.14
P/E Ratio
$58.20
★ N/A
Revenue Growth
★ 7.81
N/A
52 Week Low
$28.56
$26.96
52 Week High
$38.42
$54.98

Technical Indicators

Market Signals
Indicator
BFS
HROW
Relative Strength Index (RSI) 39.14 34.95
Support Level $28.56 N/A
Resistance Level $35.04 $30.28
Average True Range (ATR) 0.65 1.29
MACD 0.03 0.05
Stochastic Oscillator 22.93 18.92

Price Performance

Historical Comparison
BFS
HROW

About BFS Saul Centers Inc.

Saul Centers Inc is a self-managed real estate investment trust which invests in, operates and develops retail and commercial properties. The company's portfolio includes community and neighbourhood shopping centres, office properties, and mixed-use properties. Properties are located in the Washington, D.C. and Batlimore metropolitan areas. Saul Centers operates through two business segments: Shopping Centers segment, which contribute the maximum portion of total revenue; and mixed-use properties.Mixed-Use Properties segment include office, retail and multi-family residential use.

About HROW Harrow Inc.

Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.

Share on Social Networks: